Christina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $95.91, for a total value of $218,099.34. Following the sale, the chief operating officer now directly owns 69,383 shares of the company’s stock, valued at approximately $6,654,523.53. This trade represents a 3.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Christina Rossi also recently made the following trade(s):

• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total value of $216,257.40.

Blueprint Medicines Price Performance

BPMC opened at $90.14 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company’s 50-day moving average price is $92.48 and its 200 day moving average price is $97.13. Blueprint Medicines Co. has a fifty-two week low of $72.24 and a fifty-two week high of $121.90. The firm has a market cap of $5.73 billion, a price-to-earnings ratio of -42.72 and a beta of 0.59.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million for the quarter, compared to the consensus estimate of $127.56 million. During the same quarter last year, the business posted ($2.20) EPS. The business’s revenue was up 126.5% on a year-over-year basis. As a group, sell-side analysts expect that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on BPMC. UBS Group began coverage on shares of Blueprint Medicines in a research report on Thursday, October 24th. They set a “neutral” rating and a $88.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a research report on Monday, December 9th. HC Wainwright reissued a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. Wedbush reaffirmed an “outperform” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Thursday, November 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $122.11.

Institutional Trading of Blueprint Medicines

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its holdings in shares of Blueprint Medicines by 22.5% during the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after buying an additional 729,055 shares during the last quarter. Millennium Management LLC increased its position in Blueprint Medicines by 540.0% in the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock valued at $67,646,000 after acquiring an additional 529,566 shares during the period. 1832 Asset Management L.P. raised its stake in Blueprint Medicines by 200,159.4% during the 2nd quarter. 1832 Asset Management L.P. now owns 502,651 shares of the biotechnology company’s stock valued at $54,176,000 after acquiring an additional 502,400 shares in the last quarter. State Street Corp boosted its position in Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock worth $255,827,000 after acquiring an additional 385,818 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of Blueprint Medicines by 161.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock worth $45,888,000 after purchasing an additional 306,079 shares in the last quarter.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.